Obesity, GLP-1s, and the Evidence: What the Data Tells Us

Beyond the Endpoint

In this second episode of our obesity series, preventive cardiologist Neha Pagidipati sheds light on the discovery, impact, and uses of GLP-1s, like Ozempic and Mounjaro. Learn about the impact these medications are having on diabetes, heart disease, and weight management. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-4-obesity-glp-1s-and-evidence-what-data-tells-us